Last reviewed · How we verify
Pneumococcal vaccine GSK513026
At a glance
| Generic name | Pneumococcal vaccine GSK513026 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal vaccine GSK513026 CI brief — competitive landscape report
- Pneumococcal vaccine GSK513026 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI